Enlaza Therapeutics, a trailblazer in the realm of covalent biologics, has announced an impressive funding round of $100 million. This capital infusion will propel the company's innovative mission to develop advanced protein therapeutics that promise not only increased efficacy but also enhanced safety for patients suffering from a range of complex diseases. At the heart of Enlaza’s groundbreaking approach is its proprietary War-Lock™ platform, which utilizes cutting-edge synthetic biology technology to enable site-specific covalent coupling driven by precise drug binding. This innovative mechanism allows for the creation of first-in-class therapeutics that can selectively target disease pathways while minimizing side effects. With this significant funding, Enlaza Therapeutics aims to accelerate its research and development efforts, expand its pipeline of covalent biologics, and advance its clinical trials. The funds will also support the company’s strategic initiatives to further validate its technology platform, foster key partnerships, and enhance its capabilities in bringing these pioneering treatments to market. As the biopharmaceutical landscape continues to evolve, Enlaza’s commitment to developing transformative therapies places it at the forefront of medical innovation. The potential impact of their work not only stands to benefit patients worldwide but also reinforces Enlaza Therapeutics' reputation as a leader in the development of next-generation biologics. As they embark on this exciting journey, the company is well-equipped to make significant strides towards redefining treatment paradigms in healthcare.
Enlaza Therapeutics Secures $100M in Series A Funding to Advance Covalent Biologics Pipeline
Recently funded · $100.0M Series aBiotechnology
Get the full Enlaza Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
